Cytokines under investigation for the treatment of metastatic melanoma include IL-21, which produced an ORR of 22.5% [244], and is tested both alone and in phase I trials in combination with anti-CTLA4 (NCT01489059) and anti-PD1 antibody (NCT01629758). Here, CTLA4 is linked to metastatic melanoma.